# Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies

> clinical trial · VERIFIED · 2026-07-09

Status: NOT_YET_RECRUITING · Sponsor: National Heart, Lung, and Blood Institute (NHLBI) · Condition: Lung Transplantation

- Company: National Heart, Lung, and Blood Institute (NHLBI)
- Sector: Lung Transplantation
- Primary source: https://clinicaltrials.gov/study/NCT06948097

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.